FDA Lifts Hold on Vanda Pharmaceuticals' Motion Sickness Drug

By Katherine Hamilton

Vanda Pharmaceuticals said the Food and Drug Administration has lifted the partial clinical hold on its motion sickness drug tradipitant .

The decision allows the Washington, D.C., company to extend clinical studies of tradipitant in treating motion sickness and eliminates the need for an additional six-month dog toxicity study.

The FDA agreed with Vanda's position that motion sickness is an acute, self-limiting physiologic response rather than a chronic or chronic-intermittent condition.

The ongoing review of tradipitant's new drug application for the prevention of vomiting from motion sickness is still on track.

Write to Katherine Hamilton at [e-mail]

(END) Dow Jones Newswires

12-04-25 1720ET